Results 201 to 210 of about 152,178 (350)

Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience [PDF]

, 2021
Katalin Boér, Zsuzsanna Kahán, László Landherr, Tibor Csőszi, Károly Máhr, Ágnes Ruzsa, Zsolt Horváth, Barna Budai, Gábor Rubovszky   +8 more
openalex   +1 more source

The safety of trastuzumab deruxtecan (T‐DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta‐analysis

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Background Although trastuzumab deruxtecan (T‐DXd) demonstrated unprecedented intracranial efficacy in HER2‐positive breast cancer brain metastases (BCBM), its association with interstitial lung disease (ILD)/pneumonitis posed a critical safety concern in this high‐risk population.
Yiwen Ma, Xiaorui Li, Yujun Jiang, Liping Xiao, Tao Sun   +4 more
wiley   +1 more source

Resistance to HER2-targeted therapy

Research in Molecular Medicine, 2013
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment.
Reza Valadan, Alireza Rafiei, Mohsen Tehrani, Forough Nejatollahi   +3 more
doaj  

Clinical experience with lapatinib in patients with ErbB2-overexpressing metastatic breast cancer [PDF]

, 2008
Blackwell KL, Burris, Christianson TA, Clayton AJ, Di Leo A, Lin NU, Michael Untch, Nadia Harbeck, Rusnak DW, Schwartz G, Sibylle Loibl, Stemmler J, Storniolo A, Volker Heinemann   +13 more
core   +3 more sources

Life-Saving Reduced Dose of Trastuzumab-Deruxtecan in Metastatic HER2-Low Metastatic Breast Cancer with Major Hepatic Insufficiency: A Case Report [PDF]

Nahed Damaj, Ghida Diab, Gilbert Freiha, Bryan Youssef, Joseph Amara, Celina Douaihy, Lina Menassa, Lynn Abdo, Serge Fenianos, Elie Haddad, Georges Dabar, Roland Eid, Hampig Raphaël Kourie   +12 more
openalex   +1 more source

Minimal residual disease in solid tumors: Clinical applications and future directions

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor‐derived fragments that persist after treatment and remain undetectable by conventional imaging or protein‐based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection.
Theresa Abdo, Ahmad Alhalabi, Sacha Yaghi, Mohammad Aloran, You Li, María Herrán, Rami Tfayli, Thomas A. Samuel, Zeina Nahleh   +8 more
wiley   +1 more source

Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV. [PDF]

PLoS One
Liu C, Ren Y, Luo X, Zhou P, Du X, Wang Q, Han X, Xu Y, Wang P, Zhao D, Yang H.   +10 more
europepmc   +1 more source

Severe Hepatic Adverse Event Induced by Anti‐HER2 Therapy in Breast Cancer: A Case of Successful Immunotherapy With Baricitinib

ACR Open Rheumatology, Volume 8, Issue 2, February 2026.
Yufei Li, Yifan Wang, Miao Shao, Jing He
wiley   +1 more source

Triple Negative Breast Cancer With Choroidal Metastasis Responsive to Sacituzumab Govitecan and Radiation Therapy

Cancer Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background Orbital metastases are rare in patients with breast cancer. However, medical management of orbital metastases is limited by the inability of treatment options to penetrate the blood‐brain barrier. In patients with triple negative breast cancer (TNBC), these treatment options are further limited.
Nellie Nafissi, Aditya Mahadevan, Elaine Chiao, Nejina Rijal, Ritesh Parajuli   +4 more
wiley   +1 more source

In vivo detection of HER2-positive breast cancer and sentinel lymph node metastasis using activatable ICG-conjugated Trastuzumab. [PDF]

Front Oncol
Liu Y, Isa M, Nakajima T.
europepmc   +1 more source